The Flow has not summarised this story yet — read it at arXiv Computer Vision.
arXiv:2609.15888v1 Announce Type: cross Abstract: Deep networks trained on structural MRI for Alzheimer's disease (AD) staging often reach reasonable accuracy while attending to anatomically irreleva...
arXiv:2606. 18354v1 Announce Type: cross Abstract: Recent advances in generative machine learning models have significantly improved medical imaging, offering promising solutions for data augmentation, privacy preservation, and improved model generalization.
The paper presents a multimodal 3D convolutional neural network that classifies Alzheimer’s disease using raw OASIS 1 MRI volumes. It fuses structural T1 images with gray matter, white matter, and cerebrospinal fluid probability maps to capture complementary neuroanatomical information. Evaluated with 5‑fold subject‑level cross‑validation, the model achieves a mean accuracy of 72.34 % and an ROC AUC of 0.7781, with GradCAM visualizations highlighting anatomically relevant regions such as the medial temporal lobe and ventricles.
arXiv:2608. 08173v1 Announce Type: cross Abstract: Longitudinal MRI enables sensitive measurement of structural brain change for studying aging and neurodegenerative disease.
The study presents an explainable multimodal deep‑learning framework that combines a 3D CNN for T1‑weighted MRI with a feedforward network for harmonized clinical and demographic data to diagnose Alzheimer’s disease. Using 6,479 ADNI records and 1,703 OASIS‑3 records, the authors compare various model configurations on three‑way and pairwise diagnostic tasks, finding that performance and explanations vary by task, modality, fusion strategy, and cohort. SHAP and Integrated Gradients consistently highlight the MMSE score as the most influential tabular feature, while CAM‑based explanations differ across model setups and cohorts, indicating that explainability is not a stable property under cohort shift.
arXiv:2606. 17867v1 Announce Type: cross Abstract: Despite increasing adoption of multimodal approaches in Alzheimer's Disease (AD) research -- aimed at integrating molecular, structural, clinical, and genetic biomarkers to enhance disease characterization -- the relationships among these modalities remain poorly understood.